

# Supporting Information

Tay et al. 10.1073/pnas.1406674111


## SI Methods

**In Vitro T-Cell Proliferation Assays with Hepatocytes.** Mice were treated with  $10^{11}$  vector genome copies (vgc) of recombinant adenoassociated virus (rAAV).GFP-membrane-anchored form of ovalbumin (rAAV.GFP-mOVA) or rAAV.GFP-mOVA-T4. Four days later, hepatocytes from treated and untreated mice were harvested by retrograde perfusion as described previously (1). Different numbers of hepatocytes were then cocultured with  $10^5$  OT-I lymph node (LN) cells labeled with 5  $\mu$ M carboxy-fluorescein succinimidyl ester (CFSE) in RPMI medium supplemented with 10% FCS and 50  $\mu$ M  $\beta$ -mercaptoethanol. Medium was also supplemented with 20 ng/mL IL-2 (BD Biosciences) in some cultures. After 3 d of incubation at 37 °C with 5% CO<sub>2</sub>, cells were restimulated with synthetic SIINFEKL pep-


ptide and the percentages of CD8<sup>+</sup> OT-I cells producing IFN- $\gamma$  were determined by intracellular cytokine staining as described earlier.

**Quantification of Cytokine mRNA Expression by Quantitative PCR.** CD8<sup>+</sup> CD45.1<sup>+</sup> OT-I were sorted after purification from the livers of AAV.mOVA-treated B6 mice and restimulated ex vivo with SIINFEKL (0.1  $\mu$ g/mL) for 8 h. Total RNA was isolated using the RNeasy Micro Kit (Qiagen), and cDNA was synthesized by using MMLV Super-Script II and random hexamers (Promega). Total cDNA was diluted 1:5 and amplified by using TaqMan gene-specific primer and probe sets (Applied Biosystems) in TaqMan quantitative PCR master mix (Applied Biosystems). Real-time acquisition and analysis was performed on the MX3005P real-time PCR system (Stratagene).


1. Bertolino P, Trescol-Biémont MC, Rabourdin-Combe C (1998) Hepatocytes induce functional activation of naive CD8<sup>+</sup> T lymphocytes but fail to promote survival. *Eur J Immunol* 28(1):221–236.




**Fig. S1.** Expression of OVA by most hepatocytes following administration of rAAV.mOVA does not lead to hepatotoxicity. (A) OVA expression on purified hepatocytes from B6 mice injected i.v. with  $5 \times 10^{10}$  vgc rAAV.mOVA 7 d earlier (black line) compared with untreated controls (shaded) assessed by flow cytometry. Overlays are representative of two independent experiments. (B) Merged confocal microscopic images of liver sections showing OVA expression in livers from B6 mice treated 3 wk earlier with  $5 \times 10^{10}$  vgc rAAV.mOVA compared with untreated mice. OVA expression (green) did not colocalize with F4/80<sup>+</sup> Kupffer cells (red, *Left*) or CD31<sup>+</sup> liver endothelial cells (red, *Right*). Images are representative of sections from four mice. (Scale bars: 100  $\mu$ m.) (C) Serum alanine aminotransferase levels in B6 mice after treatment with  $10^{11}$  vgc rAAV.mOVA, compared with age-matched controls that did not receive rAAV.mOVA. Dashed line indicates average alanine aminotransferase value from 15 control mice.




**Fig. S2.** Hepatocyte-specific H-2K<sup>b</sup> expression induced by rAAV.K<sup>b</sup>-treatment. (A) Surface H-2K<sup>b</sup> expression on purified, live (PI<sup>-</sup>) hepatocytes from B10.BR mice treated with rAAV.K<sup>b</sup> ( $5 \times 10^{10}$  vgc) 7 d earlier compared with untreated controls. (B) Percentages of H-2K<sup>b</sup> hepatocytes 7 d after B10.BR mice were treated with indicated doses of rAAV.K<sup>b</sup>. Representative data from three mice per group are shown. (C) Merged confocal microscopic images of liver sections showing that H-2K<sup>b</sup> expression (green) in liver does not colocalize with F4/80<sup>+</sup> Kupffer cells (red, *Left*) or CD31<sup>+</sup> liver endothelial cells (red, *Right*). (Scale bars: 100  $\mu$ m.) (D) Lack of H-2K<sup>b</sup> expression by CD45<sup>+</sup> leukocytes isolated from the liver, liver-draining LN, and spleen of rAAV.K<sup>b</sup>-treated B10.BR mice (black line), compared with untreated B10.BR (shaded) or B6 mice (dashed). B6 leukocytes were used as positive controls for H-2K<sup>b</sup> expression. Plots represent three mice from two independent experiments.




**Fig. S3.** Expansion of OT-I T cells in response to rAAV.mOVA treatment. Absolute OT-I T-cell counts performed 7 d after OT-I T cells were transferred into B6, Alb-K<sup>b</sup>.bm1, or bm1 mice treated with rAAV.mOVA and/or rAAV.K<sup>b</sup> ( $5 \times 10^{10}$  vgc each) the following day.




**Fig. 54.** Des T-cell proliferation in response to rAAV.K<sup>b</sup> treatment. (*Upper*) Des T cell (rectangle gate, CD8<sup>+</sup>Des<sup>+</sup>) proliferation 48 h after transfer of  $4 \times 10^6$  Des recombinase activating gene<sup>-/-</sup> LN cells into B10.BR mice pretreated with rAAV.K<sup>b</sup> ( $5 \times 10^{10}$  vgc) 7 d earlier. (*Lower*) CD44 expression by Des T cells 2 wk after transfer into B10.BR mice treated with rAAV.K<sup>b</sup> ( $5 \times 10^{10}$  vgc) 7 d before T-cell transfer, compared with untreated B10.BR controls (shaded). Plots representative of four or five mice in each group.




**Fig. 55.** Cytotoxicity of transferred OT-I.bm1 cells transferred into Alb-K<sup>b</sup>.bm1 mice treated with rAAV.mOVA. In vivo cytotoxicity to SIINFEKL-coated splenocytes measured 3 wk after  $2 \times 10^6$  OT-I.bm1 LN cells were transferred into Alb-K<sup>b</sup>.bm1 mice treated with low-dose ( $5 \times 10^8$  vgc) or high-dose ( $5 \times 10^{10}$  vgc) rAAV.mOVA 1 d after OT-I.bm1 transfer.




**Fig. S6.** Effects of in vitro stimulation of OT-I T cells by hepatocytes transduced with high- vs. low-affinity ligand. C57BL/6 mice were administered  $1 \times 10^{11}$  vgc of rAAV.GFP-mOVA or rAAV.GFP-mOVA-T4. Hepatocytes were harvested 4 d later by retrograde perfusion and collagenase digestion. Varying numbers of hepatocytes were then cocultured in RPMI medium supplemented with 10% FCS and 50  $\mu$ M  $\beta$ -mercaptoethanol with  $1 \times 10^5$  OT-I LN cells previously labeled with 5  $\mu$ M CFSE. Medium was also supplemented with 20 ng/mL IL-2 (BD Biosciences) in some cultures. After 3 d of incubation at 37  $^{\circ}$ C with 5%  $\text{CO}_2$ , cells were restimulated with synthetic SIINFEKL peptide and the percentages of  $\text{CD8}^+$  OT-I cells producing IFN- $\gamma$  determined by intracellular cytokine staining as described for Fig. 7. (A) Representative FACS plots demonstrating division (CFSE dilution) and IFN- $\gamma$  production by OT-I T cells cocultured with varying numbers of hepatocytes as indicated, transduced with high- or low-affinity ligand, in the presence or absence of IL-2. (B) CFSE division profiles of OT-I T cells under conditions as per A; (C) Numbers of dividing ( $\text{CFSE}^{\text{low}}$ ) cells producing IFN- $\gamma$  following restimulation under the aforementioned conditions. Plots represent mean  $\pm$  SEM of two replicates per group. This experiment was repeated once with similar results.



**Fig. S7.** Treatment with rAAV.GFP-mOVA and rAAV.GFP-mOVA-T4 lead to the same level of hepatocyte transduction. Percentage of GFP-expressing hepatocytes isolated from B6 mice treated with various doses of rAAV.GFP-mOVA or rAAV.GFP-mOVA-T4 7 d earlier ( $n = 1$  mouse per data point).



**Fig. 58.** Intrahepatic OT-I T cells mice treated with a high dose of rAAV.mOVA did not express IFN- $\gamma$  and TNF- $\alpha$  upon peptide restimulation. IFN- $\gamma$  and TNF- $\alpha$  mRNA expression was analyzed in sorted OT-I T cells transferred into B6 mice treated with high- and low-dose AAV.mOVA at week 3 after transfer. T cells were restimulated ex vivo with SIINFEKL (0.1  $\mu$ g/mL) for 8 h. In the first experiment, 5,000–10,000 cells per group were sorted; in the second experiment, 88,000 cells per group were sorted. The relative gene expression to unstimulated OT-I sorted from untreated B6 mice was calculated by using the  $2^{-\Delta[\Delta]Ct}$  method after Ct values of the gene of interest were normalized to the average Ct values of the three housekeeping genes (HRPT, GAPDH, and  $\beta$ -actin). Ct values obtained for IL-2, IL-17A, and IL-10 in the positive control sample (OT-I sorted from untreated B6 mice stimulated ex vivo with PMA and ionomycin for 8 h) were 32, 34, and 40, respectively, whereas the same cytokines were not detected in OT-I sorted from all AAV-treated mice (all Ct values >45).



**Fig. S9.** Function of OT-I T cells following adoptive transfer of a small inoculum into mice treated with rAAV.mOVA. 1000 OT-I LN cells (500 CD8 OT-I T cells) were adoptively transferred into C57BL/6 mice. One day later, mice were administered a low dose ( $5 \times 10^8$  vgc) or a high dose ( $5 \times 10^{10}$  vgc) of rAAV.mOVA. Liver leukocytes were harvested 3 wk later, and CD107 degranulation assay and intracellular staining for IFN- $\gamma$  was performed as described for Fig. 7.